

# Gastric Cancer and PD-L1 Expression: Morphology, Biomarker Landscape, and Case Analysis

When: Tuesday, 24<sup>th</sup> March 2026

Time: 12:00 p.m. to 1:00 p.m.

Location: Room #2

Free lunch for all attendees – limited spaces available

**Abstract:** Gastric cancer is a biologically diverse and diagnostically complex disease, requiring rigorous pathologic evaluation to support modern precision oncology. This session brings together three pathology perspectives to provide a focused and practical framework for understanding PD L1 assessment within the broader gastric biomarker context.

The program begins with an overview of key histologic and molecular features that define gastric cancer heterogeneity, establishing the foundational context necessary for accurate biomarker interpretation. Building on this, the second segment examines the current biomarker landscape with an emphasis on PD L1 testing, highlighting scoring methodologies, assay considerations, and essential pre analytic and analytic best practices that directly impact diagnostic reliability and reproducibility. The final segment presents real world gastric cancer cases to illustrate how PD L1 assessment is integrated with routine pathologic findings to support multidisciplinary clinical decision making in alignment with evolving guidelines. Throughout the session, speakers will underscore the central role of the pathologist in ensuring accurate, consistent, and high-quality PD L1 evaluation, reinforcing how thoughtful diagnostic practice underpins reliable reporting and informed treatment planning in gastric cancer.



Deborah Jue, MD  
California, USA



Mar Iglesias Coma, MD, PhD  
Barcelona, Spain



Ashish Mogal, MD, PhD  
Arizona, USA